Aarti Pharmalabs Peer Comparison

NSE: AARTIPHARM | BSE: 543748

₹968.50

₹14.75 (1.55%)

As on 01-Oct-2026IST

Market cap

₹8,762 Cr

Revenue (TTM)

₹1,969 Cr

P/E Ratio

41.1

P/B Ratio

Div. Yield

0.4 %

Edit

	Aarti Pharmalabs	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Market cap (₹ Cr)	8,762	33,904	27,051	26,327	26,160
Revenue (₹ Cr)	1,969	3,564	1,936	9,205	1,462
Net Profit (₹ Cr)	195.95	414.00	288.22	-371.81	387.35
Net Margin (%)	9.91	11.23	14.79	-3.93	26.01
RoE (%)	10.33	8.38	29.77	-3.85	25.18
Price to Earnings	41.11	82.89	93.86	--	67.73
Price-To-Book	4.00	6.73	20.15	3.29	15.16

Income Statement (₹ Cr)

	Aarti Pharmalabs	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Operating Revenue	1,969.05	3,564.00	1,935.80	9,205.28	1,461.80
Total Income	1,977.23	3,686.00	1,948.58	9,449.59	1,489.25
Total Expenditure	1,542.78	2,792.00	1,485.56	8,195.15	919.25
EBITDA	426.27	772.00	450.24	1,010.13	542.56
Depreciation	111.57	226.00	50.83	857.51	37.68
EBIT	314.70	546.00	399.41	152.62	504.88
Interest	52.98	217.00	40.84	342.73	3.77
Other Income	8.18	122.00	12.78	244.31	27.45
Exceptional Items	-2.80	12.00	0.00	-216.88	0.00
Profit before Tax	267.10	463.00	371.35	-162.68	528.56
Provision for Tax	71.16	49.00	83.14	209.13	141.21
Profit after Tax	195.95	414.00	288.22	-371.81	387.35

	Aarti Pharmalabs	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Shareholder's Funds	2,124.61	4,940.00	1,288.82	8,162.62	1,653.56
Minority Interest	0.00	-5.00	0.00	0.00	-1.13
Non-Current Liabilities	419.53	1,712.00	202.03	5,044.14	42.40
Current Liabilities	937.57	1,622.00	835.87	4,758.28	230.82
Total Liabilities	3,481.71	8,578.00	2,326.71	17,723.32	1,983.96

	Aarti Pharmalabs	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Non-Current Assets	1,966.64	5,343.00	519.60	10,211.52	1,026.85
Current Assets	1,397.29	2,606.00	1,681.81	7,191.66	881.27
Total Assets	3,481.71	8,578.00	2,326.71	17,723.32	1,983.96
Total Debt*	685.63	2,125.00	259.37	5,495.48	26.49
Net Current Assets	459.72	984.00	845.94	2,433.38	650.46
Contingent Liabilities	7.94	768.26	19.09	95.72	17.25

	Aarti Pharmalabs	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Cash From Operating Activities	261.93	390.00	205.05	1,652.60	292.17
Cash Flow from Investing Activities	-430.72	-241.00	-409.72	-826.03	-265.94
Cash from Financing Activities	170.58	-54.00	283.07	-38.98	4.10
Net Cash Inflow / Outflow	1.80	95.00	78.39	787.59	30.33

	Aarti Pharmalabs	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
ROCE (%)	10.77	6.79	29.22	1.24	32.42
ROE (%)	10.33	8.38	29.77	-3.85	25.18
ROA (%)	6.13	4.94	24.77	-2.21	21.93
EBIT Margin (%)	15.98	15.32	20.63	1.66	34.54
Net Margin (%)	9.91	11.23	14.79	-3.93	26.01
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Aarti Pharmalabs	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Revenue Growth (%)	1.20	18.37	46.65	0.78	40.90
EBIT Growth (%)	-14.33	252.26	62.13	-70.53	124.50
Net Profit Growth (%)	-26.00	377.85	89.49	-1,383.43	104.15
EPS Growth (%)	-18.10	1,001.33	78.60	-484.84	42.32
Book Value Growth (%)	6.71	13.47	144.31	0.33	26.03

	Aarti Pharmalabs	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Price / Earnings	40.66	85.08	92.42	-84.14	67.73
Price / Book Value	4.00	6.73	20.15	3.29	15.16
Dividend Yield (%)	0.36	0.00	0.09	0.00	0.08
EV/EBITDA	22.14	45.81	59.89	30.16	47.85
Market Cap (₹ Cr)	5,342.07	19,071.62	12,753.19	18,108.89	20,944.75

	Aarti Pharmalabs	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Debt to Equity	0.09	0.31	0.11	0.53	0.02
Short term debt to equity ratio	0.22	0.09	0.05	0.09	0.02
Current Ratio	1.49	1.61	2.01	1.51	3.82
Quick Ratio	0.81	1.06	1.14	0.87	2.82
Interest Coverage	6.04	3.13	10.09	0.53	141.16

	Aarti Pharmalabs	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Debtors to sales (%)	29.62	16.50	26.28	23.44	24.80
Asset Turnover	0.62	0.43	1.66	0.55	0.83
Receivable days	116.23	58.75	40.13	78.20	88.98
Inventory Days	123.16	75.82	60.29	93.30	56.04
Payable days	133.87	186.21	232.47	226.14	99.95
Cash Conversion Cycle	105.52	-51.64	-132.04	-54.64	45.07

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.